Cited by 33Mesenchymal stem cell researchBone fractures and treatmentsBone Tissue Engineering Materials

The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.

Clinical Application of Adipose Derived Stem Cells for the Treatment of Aseptic Non-Unions: Current Stage and Future Perspectives—Systematic Review

Open access
Smakaj, Amarildo, De Mauro, Domenico, Rovere, Giuseppe, Pietramala, Silvia, Maccauro, Giulio, Parolini, Ornella, Lattanzi, Wanda, Liuzza, Francesco·2022·International Journal of Molecular Sciences

Abstract

Fracture non-union is a challenging orthopaedic issue and a socio-economic global burden. Several biological therapies have been introduced to improve traditional surgical approaches. Among these, the latest research has been focusing on adipose tissue as a powerful source of mesenchymal stromal cells, namely, adipose-derived stem cells (ADSCs). ADSC are commonly isolated from the stromal vascular fraction (SVF) of liposuctioned hypodermal adipose tissue, and their applications have been widely investigated in many fields, including non-union fractures among musculoskeletal disorders. This review aims at providing a comprehensive update of the literature on clinical application of ADSCs for the treatment of non-unions in humans. The study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Only three articles met our inclusion criteria, with a total of 12 cases analyzed for demographics and harvesting, potential manufacturing and implantation of ADSCs. The review of the literature suggests that adipose derived cell therapy can represent a promising alternative in bone regenerative medicine for the enhancement of non-unions and bone defects. The low number of manuscripts reporting ADSC-based therapies for long bone fracture healing suggests some critical issues that are discussed in this review. Nevertheless, further investigations on human ADSC therapies are needed to improve the knowledge on their translational potential and to possibly achieve a consensus on their use for such applications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms23063057

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • There was no incidence of ASCs promoting a pro-tumor tumor microenvironment in the clinical studies of ASCs for non-unions post OS resection.

    “Importantly, there was no incidence of ASCs promoting a pro-tumor TME.”

    From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [89]

    The Discussion (§4.2; page unavailable) reports that the reviewed adipose-derived stem-cell graft studies found no oncological side effects, and the Results (§3; page unavailable) report no further complications beyond those described. That supports an absence of reported clinical oncological events, but the review does not report assessing whether the cells promoted a pro-tumor microenvironment. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • In two clinical studies of ASCs for aseptic non-unions post oncological resection of OS, all patients experienced favorable general clinical outcomes characterized by successful fracture healing and effective filling of bone defects.

    “In both studies, it was observed over time that all patients experienced favorable general clinical outcomes characterized by successful fracture healing and effective filling of bone defects [89,107,108].”

    From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [89]

    The Results (page not provided) report fracture healing and bone-defect filling in patients followed across the included studies. However, three patients did not achieve consolidation and required further surgery, so the claim that all patients healed overstates the review's findings. (LLM, conf=0.90)

    Experimental — accuracy not yet measured
  • Scaffold-free ASCs have the ability to promote osteogenesis without oncological side effects short-term (within 3 months) and long-term (up to 4 years) post-transplantation.

    “The results showed that scaffold-free ASCs have the ability to promote osteogenesis without oncological side effects short-term (within 3 months) and long-term (up to 4 years) post-transplantation.”

    From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [89]

    The Discussion (§4.2; page unavailable) reports that scaffold-free adipose-derived grafts helped restore bone anatomy and function in nonunions, with no oncological side effects reported. The Results (§3; page unavailable) give a mean follow-up of about 27 months, but our copy does not establish the claimed short-term (within 3 months) and long-term (up to 4 years) time points. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • In Vériter et al., three osteosarcoma patients who received scaffold-free ASCs post wide bone resection showed adequate bone regrowth filling in the bone defect at 54, 27, and 48 months follow-up, respectively, with no evidence of prolonged inflammation or neoplastic growth.

    “In Vériter et al. study, three osteosarcoma patients received scaffold-free ASCs post wide bone resection. In all three patients at the 54, 27, and 48 months follow-up, respectively, there was an adequate bone regrowth filling in the bone defect, with no evidence of prolonged inflammation or neoplastic growth [89,107].”

    From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [89]

    Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured
  • Results from some studies have shown that the use of non-scaffolded MSCs can induce bone regrowth in patients with bone lesions or defects.

    “While there has been less research on non-scaffolded ASCs in bone regrowth, results from some studies have shown that the use of non-scaffolded MSCs can induce bone regrowth in patients with bone lesions or defects [89].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

1 of the 50 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Metadata

Authors
Smakaj, A., De Mauro, D., Rovere, G., Pietramala, S., Maccauro, G., Parolini, O., Lattanzi, W., & Liuzza, F.
Affiliations
  • Università Cattolica del Sacro Cuore (IT)
  • Department of Aging, Neurological, Orthopaedic and Head-Neck Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy
  • Agostino Gemelli University Polyclinic (IT)
Corresponding author
  • Lattanzi, Wanda
  • Liuzza, Francesco
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2022-03-11
Volume
23
Issue
6
Pages
3057
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4220746626
Cited by
31
References
50
Citations by year
2026: 4 · 2025: 7 · 2024: 8 · 2023: 7 · 2022: 5
FWCI
1.12
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, cc-by)
Funders
Università Cattolica del Sacro Cuore
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone fractures and treatments
  • Physical Sciences › Engineering › Biomedical Engineering › Bone Tissue Engineering Materials
Keywords
adipose-derived stem cells, aseptic nonunion, nonunion, mesenchymal stem cells, stromal vascular fraction, cell therapy, bone regeneration, bone defects, clinical application
MeSH terms
Adipose Tissue, Humans, Adipocytes, Regenerative Medicine, Mesenchymal Stem Cells, Cell- and Tissue-Based Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review